Eviana Alice Breuss, MD, PhD, is the Founder and President of TENGENA, a company advancing deterministic atomic‑scale manufacturing for next‑generation microelectronics, photonics, and hybrid quantum–classical systems. She holds an MD and PhD in Clinical Pharmacology and Biochemistry, with postdoctoral training in molecular biology at Columbia University. From 2000–2010, Dr. Breuss conducted basic and clinical research at Washington State University, Columbia University, and NYU, collaborating with Harvard University, Bristol‑Myers Squibb, and Cornell University. Her background includes translational biology, nanotechnology evaluation, and the design and execution of DoD, federal, and non‑profit research programs, including INDs, regulatory submissions, and preclinical‑to‑clinical development strategies. At TENGENA, Dr. Breuss leads the development of sub‑nanometer and picometer‑scale metallic materials produced through a proprietary inline plasma‑pulse synthesis platform. This process enables oxygen‑free, contamination‑free fabrication of noble, alloyed, and compound particles with engineered electromagnetic, plasmonic, and phononic properties. These materials integrate into advanced semiconductor, photonic, and spintronic architectures, supporting high‑aspect‑ratio structures, low‑loss signal pathways, and reliable multilayer assemblies in densely stacked systems. Her team’s work spans vertical interconnects, thermal‑management structures, and next‑generation signal pathways, including engineered vias, embedded cooling features, bimetallic power conduits, and metasurface‑enabled interconnects. Dr. Breuss has served as Invited Speaker and Conference Chair at several international meetings, presenting on plasmonic sub‑nanoscale architectures, quantum‑stabilized energy systems, and Majorana‑mode behavior in plasma‑like environments. She was recently recognized as one of the Top 30 Global Women Thought Leaders for 2025, highlighted on NBC Washington.